Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma

Joel Ho(The University of Texas MD Anderson Cancer Center), Rodabe N. Amaria(The University of Texas MD Anderson Cancer Center), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Andrew J. Bishop(The University of Texas MD Anderson Cancer Center), Michael K. Wong(Roswell Park Comprehensive Cancer Center), Jane Mattei(Hospital Moinhos de Vento), Priyadharsini Nagarajan(The University of Texas MD Anderson Cancer Center), Silvana C. Faria(The University of Texas MD Anderson Cancer Center), Shirley Y. Su(The University of Texas MD Anderson Cancer Center), Devarati Mitra(Brigham and Women's Hospital), Isabella C. Glitza Oliva(The University of Texas MD Anderson Cancer Center), Roland L. Bassett(The University of Texas MD Anderson Cancer Center), Adi Diab(Cleveland Clinic), Sapna P. Patel(JSS Dental College and Hospital), Merrick I. Ross(Johns Hopkins University), Roi Weiser(The University of Texas MD Anderson Cancer Center), Ahsan Farooqi(The University of Texas MD Anderson Cancer Center), Michael A. Davies(The University of Texas MD Anderson Cancer Center), B. Ashleigh Guadagnolo(The University of Texas MD Anderson Cancer Center), Sarah B. Fisher(The University of Texas MD Anderson Cancer Center), Michael T. Tetzlaff(Hospital of the University of Pennsylvania), Curtis A. Pettaway(The University of Texas MD Anderson Cancer Center), Michelle D. Williams(The University of Texas MD Anderson Cancer Center), Jennifer L. McQuade(The University of Texas MD Anderson Cancer Center), Emily Z. Keung(The University of Texas MD Anderson Cancer Center), Larissa A. Meyer, Michael Frumovitz(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center)
Frontiers in Oncology
October 17, 2022
Cited by 55


Related Papers